Sagent Pharmaceuticals (SGNT) Reports Q4 EPS of 91c, Offers Guidance

Sagent Pharmaceuticals (NASDAQ: SGNT) reported Q4 EPS of $0.91, does not compare to the analyst estimate of $0.01. Revenue for the quarter came in at $84.4 million versus the consensus estimate of $76.2 million.

Sagent Pharmaceuticals sees FY2015 revenue of $325-375 million, versus the consensus of $343.4 million. It sees:

• Adjusted Gross Profit as a percentage of net revenue in the range of 27% to 31%; and
• Operating expenses in the range of $80 to $90 million.

For earnings history and earnings-related data on Sagent Pharmaceuticals (SGNT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Bernstein SocGen Group Reiterates Outperform Rating on JD.com, Inc (JD), 'very cheaply valued'
• Reading (RDI) Tops Q2 EPS by 4c